SCHEMBL30765962

SCHEMBL30765962

C[C@@H](Nc1nc(Br)cn(CC(=O)OC(C)(C)C)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.35
LMNA P02545 5/20 0.33
F2 P00734 1/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 4/20 0.33
HDAC6 Q9UBN7 2/20 0.33
TSHR P16473 2/20 0.33
BACE1 P56817 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MEN1 O00255 2/20 0.32
HPGD P15428 2/20 0.32
RXFP1 Q9HBX9 2/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
MAPT P10636 2/20 0.32
P2RX3 P56373 1/20 0.32
RAB9A P51151 1/20 0.32
POLB P06746 1/20 0.32
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765733 0.91 KMT2A (0.36) KMT2ALMNAKDM4EALDH1A1HDAC6
SCHEMBL30765468 0.86 LMNA (0.40) KMT2ALMNAKDM4EALDH1A1TSHR
SCHEMBL30765521 0.85 KMT2A (0.38) KMT2ALMNAKDM4EALDH1A1HDAC6
SCHEMBL30765729 0.82 ALDH1A1 (0.38) KMT2ALMNAKDM4EALDH1A1BACE1
SCHEMBL30765797 0.80 KMT2A (0.40) KMT2ALMNAF2KDM4EALDH1A1
SCHEMBL30765676 0.78 SOS1 (0.41) KMT2ALMNAKDM4EALDH1A1HDAC6
SCHEMBL30765893 0.78 ALDH1A1 (0.33) KMT2ALMNAKDM4EALDH1A1TSHR
SCHEMBL30765920 0.77 L3MBTL1 (0.41) KMT2ALMNAKDM4EALDH1A1NPSR1
SCHEMBL30765712 0.77 LMNA (0.35) LMNAKDM4EALDH1A1TSHRNPSR1
SCHEMBL30765957 0.76 ALDH1A1 (0.38) KMT2ALMNAKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed